Vol. 4 No. 01 (2020)
Original Article

Relation of Apoptosis Marker CK-18 fragment M30 with hepatic Necroinflammation in patients with HBV related Chronic Liver Disease

Full Article

HTML XML
Kazi Zakir Hossain
Assistant Registrar, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital, Dhaka
Jahangir Alam Sarker
Associate Professor, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital, Dhaka
Nooruddin Ahmad
Professor, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka
Mamun Al Mahtab
Associate Professor, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka
Fatema Tuj Johora
Assistant Professor, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital,Dhaka
Faiz Ahmad Khondaker
Associate Professor, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital, Dhaka
Md. Abdur Rahim
Associate Professor, Abdul Malek Ukil Medical College Hospital, Noahkhali
Most. Rokshana Begum
Assistant Professor, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital,Dhaka
Mohammad Shahed Ashraf
Assistant Professor, Department of Hepatology, Shaheed Suhrawardy Medical College Hospital,Dhaka

Find this Article on:

Abstract

Background and Objective: Caspase-cleaved cytokeratin 18 (CK18 M30) is a potential clinically useful biomarker in liver disease as it is released from hepatocytes during apoptosis. Chronic hepatitis B virus (HBV) infection affects more than 400 million people worldwide. For treatment of chronic hepatitis B, it is very essential to know the necro inflammatory status of liver. Cytokeratin (CK) 18 is an intermediary filament protein, expressed in hepatocytes, which is proteolytically cleaved during liver damage. In this study, we aimed to investigate whether serum CK-18 fragment M30 level significantly related with the hepatic necroinflammatory
activity in patients with HBV related compensated chronic liver disease (CLD)..Methods: This was a prospective observational study. All patients who met the inclusion and exclusion criteria were assessed for liver biopsy. The total sample was 40 patients. This study was conducted in Department of Hepatology, Bangabandhu Sheikh Mujib Medical University. Per cutaneous transthoracic liver biopsy was done. Specimens were sent to department of pathology, BSMMU for METAVIR scoring. Result: Among 40 CHB patients, the highest frequency was found at 21-30 age groups, male 31(77.5%) and female 9(22.5%), the mean HBV DNA PCR was found 5.3±1.7 (IU/ml). The mean AST and ALT were found 40.2±20.2 (U/L) and 66.4±68.2 (U/L) respectively. 16 patients were HBeAg positive and 24 patients were HBeAg negative. CK-18 M30 level in both HBeAg negative CHB patients and HBeAg positive patients were almost similar(128.8±32.91 and 123.9±28.1), Activity METAVIR score of hepatic necro inflammation
reveals, A0 was 0 (0.0%), A1 was 7(17.5%), A2 was 21(52.5%), A3 was 12(30.0%),Correlation between factors and activity METAVIR score on spearman correlation test reveals, Correlation co-efficient (r value)-age was 0.204, GGT was 0.287 , ALT was 0.333, AST was 0.360, Serum CK 18 fragment M30 level was negatively correlated with activity score of hepatic necro inflammation (r= -0.073; p=0.357). The correlation between ALT and AST with activity score were statistically significant (p<0.05). The area under the receiver-operator characteristic (ROC) curves for prediction of serum CK-18 fragment M30 level reveals - area under curve(AUC)
0.307, which gave a cut off value of 100 U/L with 78.8% sensitivity and 14.3% specificity for prediction of significant necro inflammation (A2 and A3). Conclusion: This study indicates there was no correlation between serum CK-18 fragment M30 level and hepatic necroinflammatory activity in patients with HBV related compensated chronic liver disease (CLD). As a result, CK 18 M30 cannot be used as an accurate non-invasive predictor of significant inflammatory activities in patients with CHB.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

  1. Global Hepatitis Report 2017. World Health Organization, 2017.
  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronichepatitis B virus infection: a
  3. systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546±55. https://doi.org/10.1016/S0140-6736(15)61412-X PMID: 26231459.
  4. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clinics in liver disease.2010; 14(1):1±21, vii. https://doi.org/10.1016/j.cld.2009.11.0 09 PMID: 20123436
  5. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009 May 1;49(S5):S45-55. 5. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. InSeminars in liver disease 2006 May (Vol. 26, No. 02, pp. 130-141). Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
  6. Mahtab MA, Rahman S, Karim MF, Khan M, Foster G, Solaiman S, Afroz S. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary & pancreatic diseases international: HBPD INT. 2008 Dec;7(6):595-600.
  7. Alam S, Ahmad N, Mustafa G, Alam K, Khan M. Characteristics of treatment naive chronic hepatitis B in Bangladesh: Younger populations are more affected; HBeAg-negatives are more advanced. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2008 Jan;14(1):15.
  8. Rahman S. Hepatitis B: From Blumberg to Bangladesh. Euroasian Journal ofHepato-Gastroenterology. 2012 Jan 25;1(2):42-3.
  9. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991 Mar 1;32(3):294-8.
  10. Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. European journal of gastroenterology & hepatology. 2013 Apr 1;25(4):428-34.
  11. Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PloS one. 2013 Jul 17;8(7):e68780.
  12. Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scandinavian journal of clinical and laboratory investigation. 2013 Jun 1;73(4):300-8.
  13. Mueller S, Seitz HK, Rausch V. Noninvasive diagnosis of alcoholic liver disease. World journal of gastroenterology: WJG. 2014 Oct
  14. ;20(40):14626.
  15. Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary centre in Bangladesh. Hepatobiliary & pancreatic diseases international: HBPD INT. 2009 Feb;8(1):50-2.
  16. Alam S, Ahmad N, Mustafa G, Shrestha A, Alam AK, Khan M. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver international. 2011 Jul;31(6):824-30.

Published 20-09-2021

Keywords

  • Chronic,
  • Hepatitis B,
  • Chronic Liver Disease,
  • Necro-inflammatory status,
  • Cytokeratin (CK)-18 fragment M30,
  • Hepatic Fibrosis
  • ...More
    Less

How to Cite

1.
Hossain KZ, Sarker S, Ahmad N, Mahtab MA, Johora FT, Khondaker FA, Rahim MA, Begum MR, Ashraf MS. Relation of Apoptosis Marker CK-18 fragment M30 with hepatic Necroinflammation in patients with HBV related Chronic Liver Disease. Planet (Barisal) [Internet]. 2021 Sep. 20 [cited 2024 Apr. 18];4(01):8. Available from: https://bdjournals.org/index.php/planet/article/view/24